Quick Answer
Immuneering Corp reported R&D Expense of $42.05 million for fiscal year 2025.
Immuneering Corp R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $42.05M | -12.3% |
| 2024 | $47.96M | +15.2% |
| 2023 | $41.62M | +14.8% |
| 2022 | $36.27M | +36.6% |
| 2021 | $26.54M | +76.9% |
| 2020 | $15.00M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $10.87M | -3.4% | +4.0% |
| June 30, 2025 | $10.45M | -1.9% | -8.9% |
| March 31, 2025 | $11.47M | +2.4% | +1.9% |
| September 30, 2024 | $11.25M | +12.0% | +5.6% |
| June 30, 2024 | $10.65M | +12.7% | -4.9% |
| March 31, 2024 | $11.20M | +9.7% | +11.5% |
| September 30, 2023 | $10.05M | +7.3% | +6.3% |
| June 30, 2023 | $9.45M | +18.4% | -7.4% |
- Immuneering Corp showed a decrease of -12.3% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Immuneering Corp’s r&d expense has grown by 180.3% (from $15.00 million to $42.05 million).
- The most recent figure is from Immuneering Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: